TMEM30B

Across TCGA pan-cancer cohorts, TMEM30B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TMEM30B data layer compared with 19 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher TMEM30B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TMEM30B expression acts as an unfavorable survival marker.

LIHC, KIRP, and COAD are the cancer types where TMEM30B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.028	0.775	<.001	18	view →
KIRP	OS	Median	All	0.270	0.904	<.001	12	view →
COAD	OS	Median	All	0.113	0.806	<.001	9	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TMEM30B–LIHC (OS)

Open the LIHC breakdown →